



TasP



Antiretroviral Treatment as Prevention • ANRS 12249
Ukuphila kwami, ukuphila kwethu (my health for our health)

Entry into care following universal home-based HIV testing in rural KwaZulu-Natal, South Africa *The ANRS TasP 12249 cluster-randomised trial*

M. Plazy, K. El Farouki, C. Iwuji, N. Okesola, J. Orne-Gliemann,
J. Larmarange, M.L. Newell, D. Pillay, F. Dabis, R. Dray-Spira,
for the ANRS 12249 TasP study group



Background and objectives

Benefits of early linkage to HIV care and ART initiation (1)



- ... for ensuring the best health outcomes in HIV-infected individuals
 - ▣ ↘ HIV-related morbidity and mortality (*Temprano trial: Danel et al, CROI 2015; START trial: NIH press release, May 2015*)

Benefits of early linkage to HIV care and ART initiation (2)



- ... for ensuring the best health outcomes in HIV-infected individuals
 - ▣ \searrow HIV-related morbidity and mortality (*Temprano trial: Danel et al, CROI 2015; START trial: NIH press release, May 2015*)

- ... for preventing HIV transmission to uninfected individuals
 - ▣ At individual level (*HPTN 052 trial: Cohen et al, NEJM 2011*)
 - ▣ At populational level (*Tanser et al, Science 2013*)

Towards the “Universal Test and Treat” strategy: the 90-90-90 UNAIDS target (1)



(UNAIDS, 2014)



90%

diagnosed



90%

on treatment
(no specific eligibility criteria)




90%

virally suppressed


Towards the “Universal Test and Treat” strategy: the 90-90-90 UNAIDS target (2)



(UNAIDS, 2014)



Towards the “Universal Test and Treat” strategy: the 90-90-90 UNAIDS target (3)



Many individuals lost-to-follow-up between HIV diagnosis and linkage to HIV and ART care (*Mugglin et al, Trop Med Int Health 2012; Rosen et al, PLoS Med 2011*)

Early linkage to care after home-based HIV counselling and testing (HBHCT) (1)



- **HBHCT**: strategy evaluated as **acceptable and effective** for increasing HIV testing coverage in regions of high HIV prevalence

Early linkage to care after home-based HIV counselling and testing (HBHCT) (2)



- **HBHCT**: strategy evaluated as **acceptable and effective** for increasing HIV testing coverage in regions of high HIV prevalence
- **BUT are people properly linked to care after being diagnosed HIV-positive through HBHCT?**
 - ▣ Limited data available
 - ▣ Large differences of proportions of linkage to care within three months of referral in South African studies (*Genberg, Lancet HIV 2015; J Int AIDS Soc, Naik et al, 2015; Van Rooyen et al, J Acquir Immune Defic Syndr 2013*)

Objectives



- To describe the proportion of linkage to HIV care within three months of referral following HBHCT in a rural area with high HIV prevalence
- To explore the factors associated with poor linkage to HIV care



Methods



The ANRS 12249 TasP trial (1)

- Cluster randomized trial (2011-2016) evaluating the feasibility, acceptability and efficacy of immediate ART on HIV incidence in rural KwaZulu-Natal, South Africa

Iwuji et al, Trials 2013

Orne-Gliemann et al, BMC Publ H 2015

IAS 2015: Iwuji et al (abstract n° MOAC0104)

The ANRS 12249 TasP trial (2)



Home-based HIV-testing (6 monthly rounds)

Trial area population: 22000 individuals

Referral to TasP clinic if identified HIV+

TasP clinics (1/cluster)

11 Intervention clusters: Treat all HIV+ individuals regardless of CD4 count /clinical stage

11 Control clusters: Treat all HIV+ individuals according to South African guidelines

The ANRS 12249 TasP trial (3)



Home-based HIV-testing (6 monthly rounds)

Trial area population: 22000 individuals

Referral to TasP clinic if identified HIV+

TasP clinics (1/cluster)

11 Intervention clusters: Treat all HIV+ individuals regardless of CD4 count /clinical stage

11 Control clusters: Treat all HIV+ individuals according to South African guidelines

DoH clinics

Treat all HIV+ individuals according to South African guidelines

Study population (2x5 clusters)



■ Individuals ≥ 16 years old

- identified HIV+ during HBHCT and referred to a TasP clinic from March 2012 and June 2014
- not actively in care at referral (= no visit to the local HIV programme within the past 13 months)

■ Exclusion criteria

- Inconsistent dates (death, out-migration or clinic visit)
- Period of observation < 3 months if no linkage to care
- Death or out-migration before linkage to a TasP or local HIV programme clinic within three months of referral
- Incomplete data

Statistical analysis



- **Outcome** : Linkage to HIV care within three months of referral
 - ▣ Linkage to care: attending a TasP or a DoH clinic


- **Explanatory covariates:** collected at referral (before HIV identification)
 - ▣ Socio-demographic
 - ▣ HIV-related
 - ▣ Trial-related

- **Statistical method:** multivariable logistic regression




Results

Selection of the study sample (1)





Selection of the study sample (2)




Description of the study sample




	Total (N=1218)	Women (N=880)	Men (N=338)
Age (years)			
16-29	41.7	45.3	32.3
30-39	27.9	26.0	32.8
40-49	15.3	14.0	18.6
50-84	15.1	14.7	16.3
Education level (n(%))			
Primary or less	37.5	35.8	42.0
Some secondary	33.2	33.3	32.8
At least completed secondary	29.3	30.9	25.2
Occupational status (n(%))			
Employed	16.4	13.0	25.4
Student	8.1	9.2	5.3
Other inactive	75.5	77.2	69.2
Knowing HV+ family member (n(%))			
Yes	37.7	41.4	28.1
No	62.3	58.6	71.9

Linkage to HIV care within three months of referral – by SEX



Linkage to HIV care within three months of referral – by ARM



Factors associated with linkage to HIV care within three months of referral (1)



Multivariable analysis (1/3) – Socio-demographic characteristics

	Total (N=1218)			Women (N=880)		Men (N=338)	
	N	% linkage	aOR [95%CI]	aOR [95%CI]		aOR [95%CI]	
Education level							
Primary or less	457	48.4	1.00 -	1.00 -		1.00 -	
Some secondary	404	34.7	0.67 [0.48-0.95]	0.65 [0.43-0.98]		0.73 [0.40-1.32]	
Completed secondary	357	30.0	0.57 [0.40-0.82]	0.56 [0.37-0.89]		0.60 [0.44-1.27]	
Occupational status							
Employed	200	42.5	1.00 -	1.00 -		1.00 -	
Student	99	18.2	0.48 [0.26-0.90]	0.54 [0.26-1.14]		0.38 [0.09-1.53]	
Inactive	919	39.7	0.96 [0.69-1.34]	1.10 [0.71-1.70]		0.74 [0.44-1.27]	

Multivariable model including age, education level, occupational status, assets, distance to clinic, ARV perceptions, HIV care status at referral, stigma, round of HIV testing, trial arm

Factors associated with linkage to HIV care within three months of referral (2)



Multivariable analysis (2/3) – HIV knowledge and perception

		Total (N=1218)			Women (N=880)		Men (N=338)	
		N	% linkage	aOR [95%CI]	aOR [95%CI]		aOR [95%CI]	
Knowing HIV+ family member								
	No	759	35.7	1.00 -	1.00 -	1.00 -	1.00 -	1.00 -
	Yes	459	42.9	1.44 [1.12-1.85]	1.49 [1.11-2.00]	1.22 [0.73-2.05]		
Would take ARVs if HIV+								
	No/DKN	78	26.9	1.00 -	1.00 -	1.00 -	1.00 -	1.00 -
	Yes	1140	39.2	2.00 [1.16-3.45]	2.09 [1.12-3.88]	1.71 [0.51-5.76]		

Multivariable model including age, education level, occupational status, assets, distance to clinic, ARV perceptions, HIV care status at referral, stigma, round of HIV testing, trial arm

Factors associated with linkage to HIV care within three months of referral (3)



Multivariable analysis (3/3) – Trial-related characteristics

	Total (N=1218)				Women (N=880)		Men (N=338)	
	N	% link.	aOR [95%CI]		aOR [95%CI]		aOR [95%CI]	
Distance to the closest TasP clinic								
0-1 km	443	45.8	1.00	-	1.00	-	1.00	-
1-2 km	431	34.3	0.58	[0.44-0.78]	0.53	[0.38-0.75]	0.77	[0.44-1.35]
2-5 km	344	34.0	0.57	[0.42-0.78]	0.52	[0.36-0.75]	0.77	[0.42-1.38]
HIV care status at referral								
LTFU 13-24 months	196	57.1	1.00	-	1.00	-	1.00	-
LTFU >24 months	193	43.0	0.57	[0.38-0.87]	0.61	[0.38-0.98]	0.49	[0.20-1.20]
Already diagnosed	305	32.8	0.40	[0.27-0.59]	0.40	[0.26-0.63]	0.38	[0.17-0.84]
Newly diagnosed	524	33.0	0.40	[0.28-0.57]	0.43	[0.28-0.65]	0.33	[0.16-0.66]

Multivariable model including age, education level, occupational status, assets, distance to clinic, ARV perceptions, HIV care status at referral, stigma, round of HIV testing, trial arm



Discussion



Summary of results

- **< 40% linkage to HIV care within three months of referral after home-based HIV testing, irrespective of gender**

- **Factors associated with lower linkage to HIV care**
 - ▣ **Socio-demographic:** high education level, being a student
 - ▣ **HIV knowledge and perception:** don't know HIV+ family member, would not take ARV's if HIV+
 - ▣ **Trial related characteristics:** longer distance to clinic, never been in HIV care before referral

- **For men: the patterns of association with linkage to HIV care were similar to those seen in women, but few reached statistical significance**
 - ▣ Lack of statistical power?

Interventions to increase linkage to HIV care (1)



Intervention 1.

**Text messages (SMS)
reminders of clinic
appointments to all
enrollees**

Interventions to increase linkage to HIV care (2)



Intervention 1.

Text messages (SMS) reminders of clinic appointments to all enrollees

For those not linked within one month of referral

Intervention 2.

Counselling and motivational support with Health System Navigators

- Phone
- Face to face visits at home or in a neutral place
- Escort to clinic

Interventions to increase linkage to HIV care (3)



Intervention 1.

Text messages (SMS) reminders of clinic appointments to all enrollees

For those not linked within one month of referral

Intervention 2.

Counselling and motivational support with Health System Navigators

- Phone
- Face to face visits at home or in a neutral place
- Escort to clinic

For those not linked after Intervention 2

Intervention 3.

Home-based ART initiation and care with CD4 point-of-care (with the aim to encourage people to go to clinic)



Acknowledgements

- Trial participants
 - Africa Centre staff
 - Traditional Authorities
 - Department of Health, South Africa
 - Merck/Gilead
- The IAS organizers for the scholarship



ANRS 12249 Study Group: François Dabis (co-PI), Marie-Louise Newell (co-PI), Deenan Pillay (co-PI), Collins Iwuji (South coordinator), Joanna Orne-Gliemann (North coordinator), Till Bärnighausen, Eric Balestre, Sylvie Boyer, Alexandra Calmy, Vincent Calvez, Marie-Laure Chaix, Rosemary Dray-Spira, Kamal El Farouki, Kenneth Freedberg, Kobus Herbst, John Imrie, Sophie Karcher, Joseph Larmarange, France Lert, Richard Lessells, Thembisa Makowa, Anne-Geneviève Marcelin, Laura March, Nuala McGrath, Kevi Naidu, Colin Newell, Nonhlanhla Okesola, Tulio de Oliveira, Melanie Plazy, Tamsen Rochat, Bruno Spire, Frank Tanser, Rodolphe Thiébaud, Johannes Viljoen, Thembelile Zuma.

